Evidence map›Paper›PMID 29772540›Full record

ReviewFrontiers in bioscience (Landmark edition)2018

Hsp70 and gama-Semino protein as possible prognostic marker of prostate cancer.

Sanjay Kumar, Sanjeev Gurshaney, Yori Adagunodo, Erica Gage, Shezreen Qadri, Mahak Sharma, Shalie Malik, Upender Manne, Udai P Singh, Rajesh Singh and 1 more

Abstract readReview
In one paragraph

Review in Frontiers in bioscience (Landmark edition), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. International journal of molecular sciences · 2023
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sanjay KumarCancer Biology Research and Training Program, Department of Biological Sciences ,Alabama State University, Montgomery, AL 36104, USA.
Sanjeev GurshaneyCancer Biology Research and Training, Department of Biological Sciences, Alabama State University, Montgomery, AL 36104.
Yori AdagunodoCancer Biology Research and Training, Department of Biological Sciences, Alabama State University, Montgomery, AL 36104.
Erica GageCancer Biology Research and Training, Department of Biological Sciences, Alabama State University, Montgomery, AL 36104.
Shezreen QadriCancer Biology Research and Training, Department of Biological Sciences, Alabama State University, Montgomery, AL 36104.
Mahak SharmaCancer Biology Research and Training, Department of Biological Sciences, Alabama State University, Montgomery, AL 36104.
Shalie MalikCancer Biology Research and Training, Department of Biological Sciences, Alabama State University, Montgomery, AL 36104.
Upender ManneCancer Biology Research and Training, Department of Biological Sciences, Alabama State University, Montgomery, AL 36104.
Udai P SinghDepartment of Pathology, Microbiology and Immunology, University of South Carolina, Columbia, SC 29208.
Rajesh SinghDepartment of Microbiology, Biochemistry and Immunology,Morehouse School of Medicine, 720 Westview drive, SW, Atlanta 30310 USA.
Manoj K MishraCancer Biology Research and Training, Department of Biological Sciences, Alabama State University, Montgomery, AL 36104, mmishra@alasu.edu.

Funding

Training and Education ProgramP20CA192973 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI MANNE, UPENDER · 2014 to 2017
$767k
Project 2: 2/2 The Alabama State University/UAB Comprehensive Cancer Center PartnershipP20CA192976 · NCI · ALABAMA STATE UNIVERSITY · PI MISHRA, MANOJ K. · 2014 to 2017
$598k
NCI NIH HHS P20 CA192973NCI NIH HHS P20 CA192976
6 · The paper itself

Abstract

In the United States, Prostate Cancer (PCa) is the leading cause of cancer-related mortality in men. PCa resulted in abnormal growth and function of prostate gland such as secretion of high level of gamma-seminoprotein (gama-SM)/Prostate-Specific Antigen (PSA) which could be detected in the blood. Beside gama-SM protein, the levels of heat shock proteins (Hsp70) were also observed significantly high. Therefore, gama-SM and Hsp70 are unique proteins with high potential for PCa therapeutics and diagnostics. High level of Hsp70 suppresses apoptosis, thus allowing PCa cells to exist; however, depletion of Hsp70 induces apoptosis in PCa cells. Gama-SM is the most prominent biomarker for PCa screening; however, its accuracy is still questionable. Thus, a more suitable streamline biomarker for PCa screening is urgently needed. Hsp70 and gama-SM proteins could be used as a revolutionary biomarker for PCa, and could help to identify possible therapeutic target(s). In this review article we will discuss the relationship between the Hsp70 and gama-SM proteins with PCa, their potential as a dual biomarker, and the possibility for both proteins being used as therapeutic targets.

Indexed as

Biomarkers, TumorEarly Detection of CancerHSP70 Heat-Shock ProteinsHumansMalePrognosisProstate-Specific AntigenProstatic NeoplasmsReproducibility of ResultsSensitivity and SpecificityBiomarkers, TumorHSP70 Heat-Shock ProteinsProstate-Specific Antigen

Identifiers

PMID29772540
PMCPMC5983368

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.